Recap: FibroGen Q4 Earnings
Portfolio Pulse from Benzinga Insights
FibroGen (NASDAQ:FGEN) reported Q4 earnings with a -36.0% miss on estimated EPS, recording an EPS of $-0.57 against an estimate of $-0.42. Revenue decreased by $7.23 million from the same period last year. Despite beating EPS estimates in Q3 2023, the share price dropped by 1.0% the following day.
February 26, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
FibroGen reported a significant miss in Q4 earnings with a -36.0% deviation from estimated EPS and a decrease in revenue compared to last year.
The significant miss in EPS estimates and the decrease in revenue year-over-year are likely to negatively impact investor sentiment and could lead to a short-term decrease in stock price, similar to the 1.0% drop observed after the last quarter's earnings beat.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100